临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 209216-23-9

Entecavir Hydrate

中文名称:恩替卡韦一水合物
CAS号:209216-23-9
分子式: C12H15N5O3.H2O 分子量: 295.29
产品形式: Hydrate
研发状态: Recruiting
研发用途: Chronic Hepatitis b Patients
研究机构: Sohag University
研发日期: April 15 2023
研发阶段: --
Entecavir Hydrate (ETV, Baraclude,BMS200475 Hydrate,SQ34676 Hydrate), a new deoxyguanine nucleoside analogue, is a selective inhibitor of the replication of the hepatitis B virus (HBV).

CAS: 2089288-03-7

AZD1390

CAS号:2089288-03-7
分子式: C27H32FN5O2 分子量: 477.57
产品形式: free base
研发状态: Recruiting
研发用途: Glioblastoma; Glioma; Glioblastoma Multiforme; Glioma Malignant
研究机构: Nader Sanai; Barrow Neurological Institute; Ivy Brain Tumor Center; AstraZeneca; St. Joseph''s Hospital and Medical Center Phoenix
研发日期: March 9 2022
研发阶段: Early Phase 1
AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases.

CAS: 2088323-16-2

TAS0728

CAS号:2088323-16-2
分子式: C26H32N8O3 分子量: 504.58
产品形式: free base
研发状态: Terminated
研发用途: Advanced Solid Tumors With HER2 Abnormalities; Advanced Solid Tumors With HER3 Abnormalities
研究机构: Taiho Oncology Inc.
研发日期: April 6 2018
研发阶段: Phase 1
TAS0728 (TPC 107) is a potent, selective, orally active, irreversible and covalent-binding inhibitor of HER2 (human epidermal growth factor receptor 2) with IC50 of 13 nM. TAS0728 inihibits BMX, HER4, BLK, EGFR, JAK3, SLK, LOK and human HER2 with IC50 of 4.9 nM, 8.5 nM, 31 nM, 65 nM, 33 nM, 25 nM, 86 nM and 36 nM, respectively. TAS0728 shows antitumor activity.

CAS: 2086-83-1

Berberine

中文名称:黄连素
CAS号:2086-83-1
分子式: C20H18NO4 分子量: 336.36
产品形式: free base
研发状态: Not yet recruiting
研发用途: Pharmacokinetic Study in Healthy Volunteers
研究机构: University Medicine Greifswald
研发日期: March 4 2024
研发阶段: Not Applicable
Berberine (Umbellatine), an alkaloid isolated from Rhizoma coptidis, has broad applications, particularly as an antibacterial agent in the clinic.

CAS: 208255-80-5

DAPT (GSI-IX)

中文名称:(2S)-N-[N-(3,5-二氟苯乙酰基)-L-丙氨酰]-2-苯基甘氨酸叔丁酯
CAS号:208255-80-5
分子式: C23H26F2N2O4 分子量: 432.46
产品形式: free base
研发状态: Recruiting
研发用途: Ischemic Stroke; CYP2C19 Polymorphism
研究机构: University of Virginia; American Heart Association
研发日期: April 16 2024
研发阶段: --
DAPT (GSI-IX, LY-374973) is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.

CAS: 2079939-05-0

Sirpiglenastat

CAS号:2079939-05-0
分子式: C22H27N5O5 分子量: 441.48
产品形式: free base
研发状态: Terminated
研发用途: Advanced Solid Tumor; Non Small Cell Lung Cancer Metastatic
研究机构: Dracen Pharmaceuticals Inc.
研发日期: August 31 2020
研发阶段: Phase 1 : Phase 2
Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities.